Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.
Sneha GullapalliJordi RemonLizza E L HendriksGilberto LopesPublished in: OncoTargets and therapy (2020)
Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as monotherapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- end stage renal disease
- small cell lung cancer
- ejection fraction
- combination therapy
- newly diagnosed
- locally advanced
- chronic kidney disease
- healthcare
- prognostic factors
- early stage
- radiation therapy
- systematic review
- clinical trial
- randomized controlled trial
- emergency department
- squamous cell carcinoma
- cancer therapy
- patient reported
- study protocol
- chronic pain
- electronic health record
- smoking cessation
- double blind